[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"venous-ulcer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:venous-ulcer":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,59,85,113,147,181,213,233,255],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":33,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":4},"100634355","the-gore-viabahn-fortegra-venous-stent-post-approval-study-100634355",false,"NCT07538609","The GORE® VIABAHN® FORTEGRA Venous Stent Post-Approval Study","Preoperative Inclusion Criteria:\n\n* Presence of a lesion necessitating treatment with the GORE® VIABAHN® FORTEGRA Venous Stent, as previously determined by an investigator\u002Fsub-investigator.\n* Patient is at least 18 years of age.\n* Patient is willing and able to comply with all follow-up evaluations as well as any required medication or compression regimen.\n* Patient is able to provide informed consent themself.\n\nIntraoperative Inclusion Criteria:\n\n* Patient can accommodate an appropriately sized GORE® VIABAHN® FORTEGRA Venous Stent as per reference vessel diameter (see IFU), as determined by intraoperative IVUS post pre-dilation.\n* Patient must have appropriate access vessels to accommodate the delivery sheath for the selected device size.\n* Patient has adequate landing zones free from significant disease requiring treatment beyond the proximal and distal margins of the lesion.\n* Patient has adequate inflow\u002Foutflow to\u002Ffrom the target lesion(s), per investigator\u002Fsub- investigator discretion.\n* Lesion can be traversed with a guidewire.\n\nIntraoperative Exclusion Criteria:\n\n* Patient is contraindicated for treatment with the GORE® VIABAHN® FORTEGRA Venous Stent according to the IFU.","ALL","18 Years",{"count":18,"type":19},150,"ESTIMATED","INTERVENTIONAL",[22],"NA","This study is a prospective, multicenter, single-arm post-market clinical study to evaluate the GORE® VIABAHN® FORTEGRA Venous Stent in real-world use.",[25,26,27,28,29,30,31,32],"Venous Thromboses","Venous Disease","Venous Leg Ulcer","Venous Stasis","Venous Ulcer","Venous Stenosis","Venous Occlusion","Vein Thrombosis",[34,35,36,30,37,38,39,40,41,42,26,43,44,45,46],"Vein Stent","VIAFORT","Venous Thrombosis","Gore","Venous occlusion","VIABAHN FORTEGRA","FORTEGRA","Deep Venous Insufficiency","Deep venous","DVT Treatment","Venous Stent","Venous insufficiency treatment options","Venous disease treatment options","NOT_YET_RECRUITING","2026-05-11",{"date":50,"type":51},"2026-05-14","ACTUAL",{"date":53,"type":19},"2026-10-07",{"date":55,"type":19},"2031-05",{"name":57,"class":58},"W.L.Gore & Associates","INDUSTRY",{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":4,"eligibilityCriteria":65,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":66,"targetDuration":4,"studyType":20,"phases":68,"briefSummary":69,"conditions":70,"keywords":73,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},"100476872","the-gore-viabahn-fortegra-venous-stent-iliofemoral-study-100476872","NCT05489588","The GORE® VIABAHN® FORTEGRA Venous Stent Iliofemoral Study","Evaluation of the GORE® VIAFORT Vascular Stent for Treatment of Symptomatic Iliofemoral Venous Obstruction","Preoperative Inclusion Criteria:\n\n* Patient is at least 18 years of age.\n* Patient is willing and able to comply with all follow-up evaluations as well as any required medication or compression regimen.\n* Patient is able to provide informed consent.\n* One of the following: Clinical severity class of CEAP 'C' classification ≥3 or rVCSS pain score ≥2.\n* Intention to treat the target areas with only the GORE® VIAFORT Vascular Stent.\n* Estimated life expectancy ≥1 year.\n* Patient is ambulatory (use of assistive walking device such as a cane or walker is acceptable).\n* Patient has adequate inflow to the target lesion(s), per investigator\u002Fsub-investigator discretion, involving at least a patent femoral or deep femoral vein.\n* Presence of non-malignant symptomatic unilateral iliofemoral venous obstruction.\n\nPreoperative Exclusion Criteria:\n\n* Patient has DVT in the target areas with symptom onset date greater than 14 days but less than or equal to 90 days prior to treatment.\n* Patient is a pregnant or breastfeeding woman, or a woman planning to become pregnant through the 12-month visit.\n* Patient has clinically significant (e.g., symptoms of chest pain, hemoptysis, dyspnea, hypoxia, etc.) pulmonary embolism (confirmed via Computed Tomography Angiography) at the time of enrollment.\n* Patient has a known uncorrectable bleeding diathesis or active coagulopathy meeting the following definitions (all must be tested for):\n\n  1. uncorrected INR\\>2 (not as a result of warfarin or DOAC therapy), OR\n  2. platelet count \\\u003C50,000 or \\>1,000,000 cells\u002Fmm3, OR\n  3. white blood cell count \\\u003C3,000 or \\>12,500 cells\u002Fmm3\n* Patient has impaired renal function (eGFR \\\u003C30 mL\u002Fmin\u002F1.73m2) or is currently on dialysis.\n* Patient has uncorrected hemoglobin of \\\u003C9 g\u002FdL.\n* Patient has known history of antiphospholipid syndrome (APS).\n* Patient has known homozygous or acquired coagulation defect (e.g., Protein C or Protein S deficiency) that cannot be treated with therapeutic anticoagulation.\n* Patient has a planned surgical intervention that has the potential to clinically interfere with the endpoints of this treatment (other than pre-stenting procedures such as thrombolysis or thrombectomy) within 30 days prior to or within 30 days after the planned study procedure. Examples include surgical interventions that may impact mobility, and surgical interventions that require cessation of therapeutic antiplatelet or anticoagulation within 30 days following the index procedure.\n* Patient has had or requires open deep venous surgery in the target limb.\n* Patient is currently participating in another investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the endpoints of this treatment, in the opinion of the investigator\u002Fsub-investigator. Observational studies are permitted.\n* Patient has had a previous major (i.e., above the ankle) amputation of the target lower limb.\n* Patient has known sensitivity to device materials.\n* Patient has had prior stenting or grafts in the target vessels.\n* Patient has a known or suspected active systemic infection at the time of the index procedure. Patients with a chronic infection (e.g., HIV, hepatitis C) that can be managed, and with an active clinical plan in place may be eligible.\n* Patient has known history of intravenous drug abuse within one year of treatment.\n* Patient has significant peripheral arterial disease (chronic Rutherford Type 2 or greater, acute Rutherford Type IIa or greater).\n* Patient has a BMI \\>45. Patients with a BMI of up to 45 may be enrolled provided that diagnostic quality ultrasound of the implant sites can be performed.\n* Patient is actively undergoing or plans to begin cancer treatment.\n* Patients with hypercoagulable states that are unwilling to take anticoagulant medications on a long-term basis.\n* Patient has contraindication to thrombolytics, anticoagulants, or iodinated contrast necessary for the index procedure and long-term medical therapy (contrast pre-medication is acceptable).\n\nIntraoperative Inclusion Criteria:\n\n* Presence of non-malignant unilateral obstruction of the common femoral vein, external iliac vein, and\u002For common iliac vein defined as occlusion or at least 50% reduction in target vessel lumen as measured by procedural IVUS and venogram.\n* Patient can accommodate an appropriately sized GORE® VIAFORT Vascular Stent as per reference vessel diameter (see IFU), as determined by intraoperative IVUS post pre-dilation.\n* Patient must have appropriate access vessels to accommodate the delivery sheath for the selected device size.\n* Patient has adequate landing zones free from significant disease requiring treatment within the native vessels beyond the proximal and distal margins of the lesion.\n* Patient has adequate inflow to the target lesion(s), per investigator\u002Fsub-investigator discretion, involving at least a patent femoral or deep femoral vein.\n* Lesion can be traversed with a guidewire.\n* Disease involves only unilateral iliofemoral venous segments with intent to stent all affected iliofemoral segments. Patients with disease extending into the inferior vena cava or contra-lateral iliofemoral veins who are anticipated to require endovascular or surgical treatment within 12 months after investigational device implant will be excluded.\n* Patient does not have significant (i.e., \\>20% residual thrombosis) acute thrombus within the target stent area at the time of investigational device placement. Patients with acute thrombus within the target stent area must have thrombus successfully treated prior to investigational device placement. Successful thrombus treatment is defined as reestablishment of antegrade flow with ≤20% residual thrombosis as confirmed by IVUS and venogram, AND freedom from bleeding, vascular injury, or hemodynamically significant pulmonary embolism. After successful thrombus treatment, investigational device placement can occur within the same procedure.",{"count":67,"type":19},165,[22],"This study is a prospective, non-randomized, multicenter, single-arm, clinical study to evaluate the performance, safety and efficacy of the GORE® VIABAHN® FORTEGRA Venous Stent (formerly known as GORE® VIAFORT Vascular Stent) for treatment of symptomatic iliofemoral venous obstruction.",[25,26,27,28,29,30,31,32,71,72],"Vein Occlusion","Vein Disease",[35,34,36,30,37,31,40,39,26,41,74,42,43,44,45],"Venous disease treatment Options","RECRUITING","2026-04-07",{"date":78,"type":51},"2026-04-09",{"date":80,"type":51},"2023-03-02",{"date":82,"type":19},"2031-03",{"name":57,"class":58},27,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":20,"phases":94,"briefSummary":95,"conditions":96,"keywords":97,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":112},"100501121","monitoring-of-venous-ulcers-using-a-bioimpedance-measurement-based-method-and-system-100501121","NCT05805137","Monitoring of Venous Ulcers Using a Bioimpedance Measurement Based Method and System","WoundWatch®","Inclusion Criteria:\n\n* Age at least 18 years\n* The subject has a chronic lower extremity ulcer with a primary etiology of venous insufficiency. The previous venous procedure is not an obstacle to the study\n* Compression therapy can be implemented\n* The wound is not wider than 5 cm and the electrode dressing can be placed on the wound as intended. The wound should be located above the ankle, on the skin area where the electrode dressing can be placed properly.\n* The wound is not deep with steep edges or cavity-like\n* The wound is not highly excreting\n* The wound can be expected to heal within two months (area reduced ≥ 90% from baseline)\n* The subject gives consent to the study and commits to following the instructions of the medical staff\n\nExclusion Criteria:\n\n* Clinical wound infection at the time of the study\n* The subject has an intravenous (in Tampere: A venous operation) procedure within 2 months\n* Significant arterial circulatory disorder or adherence problem that prevents compression therapy (in Tampere: Contraindication for compression therapy, e.g. significant arterial circulatory disorder or severe heart failure)\n* Subject movement 2-3 times a week during the study to the study site is difficult to arrange (in Tampere: Subject not able to commit to study visits 2-3 times a week.)\n* Diagnosed epoxy resin allergy\n* Any other reasons of potential study subject non-compliance by the opinion of the investigator\n\nAdditional local exclusion criteria in Tampere site:\n\n* Special groups, such as pregnant women\u002Fpatients trying to conceive during the study or patients with reduced autonomy\n* Subject with any implantable electrical device. Such as pacemaker or implanted defibrillator. Patient has other electrically conductive implanted material in legs. Such as a metallic prostheses.",{"count":93,"type":19},20,[22],"The purpose of this study is to investigate the functionality of a new type of wound monitoring method and measurement system for monitoring healing of venous ulcers. The system is consisted of a wound dressing with electrodes (eDressing), a bioimpedance measurement device and a mobile phone application.",[29],[98,99,100,101,102],"Venous ulcer","Monitoring","Bioimpedance","Electrode array","Wound dressing","2026-03-16",{"date":105,"type":51},"2026-03-17",{"date":107,"type":51},"2023-04-20",{"date":109,"type":19},"2026-12-31",{"name":111,"class":58},"CutoSense Oy",2,{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":20,"phases":123,"briefSummary":125,"conditions":126,"keywords":132,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":146},"100570426","phase-3-tissue-repair-gel-in-venous-leg-ulcers-us-100570426","NCT06707090","Tissue Repair Gel in Venous Leg Ulcers (US)","A Phase 3 Randomized, Parallel Group, Double-Blind Study to Evaluate the Efficacy, Tolerability, and Safety of TR987® 0.1% Gel Versus Standard of Care in the Treatment of Chronic Venous Insufficiency Leg Ulcers (VLU)","TRIVIA","Inclusion Criteria:\n\n* Adults 18 years and older\n* Venous insufficiency has been clinically diagnosed clinically and medically confirmed.\n* Females who are neither pregnant nor breastfeeding and if of child-bearing potential are on an acceptable method of birth control.\n* The Venous Ulcer should be between 2 cm2 and 12 cm2 at randomization.\n* Target ulcer age must be ≥ 4 weeks at Screening.\n* Participants must have adequate arterial flow as confirmed by ABI\u002FTBI, TB, SPP, TCPo2, or Duplex Doppler.\n* Body mass index (BMI) ≤ 50 kg\u002Fm2.\n* HbA1C ≤12%.\n\nExclusion Criteria:\n\n* Target ulcer has been treated with prohibited medications or therapies.\n* History of radiation at the target ulcer site.\n* Target ulcer decreases in area by 30% or more during screening period.\n* History of osteomyelitis at the target ulcer within 6 months of screening.\n* Participants considered nutritionally deficient.",{"count":122,"type":19},312,[124],"PHASE3","The goal of this clinical trial is to learn if TR987 0.1% gel + Standard of Care works better than Standard of Care alone to treat Venous Leg Ulcers (VLUs). It will also provide additional information about the safety of drug TR987 0.1% gel.",[27,29,127,28,128,129,130,131],"Venous Stasis Ulcer","Wound Heal","Wounds","Venous Insufficiency of Leg","Non-healing Wound",[133,134,135,136,137],"Tissue Repair","Glucoprime","TR Therapeutics","Debridement","VLU","2026-02-09",{"date":140,"type":51},"2026-02-12",{"date":142,"type":51},"2025-01-28",{"date":144,"type":19},"2028-02",{"name":135,"class":58},33,{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":154,"targetDuration":4,"studyType":20,"phases":156,"briefSummary":158,"conditions":159,"keywords":167,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":180},"100620977","phase-4-a-multicenter-prospective-controlled-modified-multi-platform-trial-assessing-the-efficacy-of-human-placental-membrane-products-and-standard-of-care-in-the-management-of-nonhealing-diabetic-foot-ulcers-and-venous-leg-ulcers-100620977","NCT07364630","A Multicenter, Prospective, Controlled Modified Multi-Platform Trial Assessing the Efficacy of Human Placental Membrane Products and Standard of Care in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers.","BIORESCUE","Inclusion Criteria:\n\n* The potential subject must be at least 18 years of age or older.\n* The potential subject must have a diagnosis of type 1 or 2 Diabetes mellitus.\n* If the potential subject has two or more ulcers, the target ulcer must be the same ulcer treated in the BIOCAMP study.\n* The potential subject must consent to using the prescribed offloading method for the duration of the study.\n* The potential subject must agree to attend the weekly study visits required by the protocol.\n* The potential subject must be willing and able to participate in the informed consent process.\n* The potential subject must have participated in the BIOCAMP trial in the SOC only arm and NOT achieved complete closure by the 12-week endpoint.\n\nExclusion Criteria:\n\n* The potential subject is known to have a life expectancy of \\\u003C 6 months.\n* The potential subject's target ulcer is not secondary to diabetes.\n* The target ulcer is infected or there is cellulitis in the surrounding skin.\n* The target ulcer exposes tendon or bone.\n* There is evidence of osteomyelitis complicating the target ulcer.\n* There is an infection in the target ulcer or in a remote location that requires systemic antibiotic therapy.\n* The potential subject is receiving immunosuppressants (including systemic corticosteroids at doses greater than 10 mg of prednisone per day or equivalent) or cytotoxic chemotherapy or is taking medications that the PI believes will interfere with wound healing (e.g., biologics).\n* The potential subject is taking hydroxyurea.\n* The potential subject has applied topical steroids to the ulcer surface within one month of TV-1.\n* The potential subject with a previous partial amputation on the affected foot that results in a deformity that impedes proper offloading of the target ulcer.\n* The potential subject has glycated hemoglobin (HbA1c) greater than or equal to 12% within 3 months of TV-1.\n* The potential subject has an acute Charcot foot, or an inactive Charcot foot, which impedes proper offloading of the target ulcer.\n* The potential subject is a woman who is pregnant or considering becoming pregnant within the next 6 months.\n* The potential subject has end stage renal disease requiring dialysis.\n* The potential subject, in the opinion of the investigator, has a medical or psychological condition that may interfere with study assessments.\n* The potential subject has a malnutrition indicator score \\\u003C17 as measured on the Mini Nutritional Assessment.\n* The potential subject did not participate in the BIOCAMP trial.\n* The potential subject participated in the BIOCAMP trial and was not randomized to the SOC only arm.\n* The potential subject participated in the BIOCAMP trial and achieved complete closure.\n* The target ulcer was treated with CAMPs, also defined as skin substitute, or hyperbaric oxygen therapy (HBOT) in the month prior to TV-1.",{"count":155,"type":19},50,[157],"PHASE4","The study is a multicenter, prospective, controlled modified multi-platform trial assessing the efficacy of human placental membrane products and standard of care in the management of nonhealing diabetic foot ulcers and venous leg ulcers.",[160,161,162,163,164,27,29,165,166],"Diabetic Foot Ulcer","Foot Ulcer Chronic","DFU","Ulcer Foot","Venous Leg Ulcer (VLU)","Leg Ulcers","Ulcer",[168,166,29,169,137,162,160,170,171],"Leg Ulcer","Venous Leg ulcer","Foot Ulcer","Diabetic foot","2026-02-05",{"date":138,"type":51},{"date":175,"type":51},"2026-01-02",{"date":177,"type":19},"2027-01",{"name":179,"class":58},"BioLab Holdings",1,{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":187,"eligibilityCriteria":188,"healthyVolunteers":189,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":190,"targetDuration":4,"studyType":20,"phases":192,"briefSummary":193,"conditions":194,"keywords":199,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":180},"100518528","fetal-cell-receptors-repertoire-100518528","NCT06031714","Fetal Cell Receptors Repertoire","\"Study of CCR Receptor Overexpression in Fetal Microchimeric Cells: Proof of Concept Before a Potential Clinical Trial\"","MoreCCR","Inclusion Criteria:\n\nCommon criteria :\n\n* Adult women,\n* Post-partum: having been pregnant for any length of time,\n* Having signed a free and informed consent form,\n* Primiparous or multiparous,\n* Affiliated to a health insurance\n\nPatients :\n\n\\- Patients with a venous, diabetic or sickle cell ulcer, or mixed ulcer\n\nControl group patients :\n\n* Volunteers,\n* Age-matched,\n* Without skin ulcers.\n\nThere are no specific criteria for children.\n\nExclusion Criteria:\n\n* Minors (for patients)\n* Under court protection, curatorship, guardianship (for patients)\n* Immunocompromised patients for any reason whatsoever\n* Refusal of consent\n* Refusal of blood and\u002For saliva samples for themselves or a member of their family",true,{"count":191,"type":19},160,[22],"The purpose of this study is to describe the transcriptomic profile of foetal cells in post-partum and more specifically to determine which chemokine receptors are overexpressed in foetal cells in post-partum women with wounds To do so, the investigators will isolate foetal cells from the peripheral blood of healthy controls post partum women as well as from post partum women with skin ulcers and then perform RNA sequencing.",[29,195,196,197,198],"Sickle Cell Ulcer","Diabetic Ulcer","Post-partum Women","Mixed Ulcer",[200,201,202],"Microchimerism","Foetal stem cells","Receptors","2025-09-05",{"date":205,"type":51},"2025-09-12",{"date":207,"type":51},"2024-02-06",{"date":209,"type":19},"2027-02-01",{"name":211,"class":212},"Assistance Publique - Hôpitaux de Paris","OTHER",{"id":214,"slug":215,"hasResults":11,"nctId":216,"briefTitle":217,"officialTitle":118,"acronym":119,"eligibilityCriteria":218,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":219,"targetDuration":4,"studyType":20,"phases":220,"briefSummary":125,"conditions":221,"keywords":223,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":232},"100570427","phase-3-tissue-repair-gel-in-venous-leg-ulcers-in-auus-100570427","NCT06707103","Tissue Repair Gel in Venous Leg Ulcers in AU\u002FUS","Inclusion Criteria:\n\n* Adults 18 years and older\n* Venous insufficiency has been clinically diagnosed clinically and medically confirmed.\n* Females who are neither pregnant nor breastfeeding and if of child-bearing potential are on an acceptable method of birth control.\n* The Venous Ulcer should be between 2 cm2 and 12 cm2 at randomization.\n* Target ulcer age must be ≥ 4 weeks at Screening.\n* Participants must have adequate arterial flow as confirmed by ABI\u002FTBI, TB, SPP, TCPo2, or Duplex Doppler.\n* Body mass index (BMI) ≤ 50 kg\u002Fm2.\n* HbA1C ≤12%.\n\nExclusion Criteria:\n\n* Target ulcer has been treated with prohibited medications or therapies.\n* History of radiation at the target ulcer site.\n* Target ulcer decreases in area by 30% or more during screening period.\n* History of osteomyelitis at the target ulcer within 6 months of screening.\n* History of cancer in the preceding 5 years (except as noted in the protocol).\n* Participants considered nutritionally deficient.",{"count":122,"type":19},[124],[27,29,127,28,128,222,130,131],"Wound",[133,134,135,136,137],"2025-03-27",{"date":226,"type":51},"2025-04-02",{"date":228,"type":19},"2025-04",{"date":230,"type":19},"2027-02",{"name":135,"class":58},12,{"id":234,"slug":235,"hasResults":11,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":239,"eligibilityCriteria":240,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":241,"targetDuration":4,"studyType":242,"phases":4,"briefSummary":243,"conditions":244,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":180},"100569721","evaluating-the-durability-of-closure-for-venous-leg-ulcers-100569721","NCT06697925","Evaluating the Durability of Closure for Venous Leg Ulcers","Prospective Multicenter Observational Study Evaluating the Durability of Closure for Venous Leg Ulcers Following a Randomized, Controlled, Clinical Trial","THORSDOTTIR","Inclusion Criteria:\n\n* 1\\. Subjects must have participated in the THOR trial and achieved complete closure by the 12-week endpoint.\n\nExclusion Criteria:\n\n* 1\\. Subjects who did not participate in the THOR trial. 2. Subjects who participated in the THOR trial and did not achieve complete closure.",{"count":18,"type":19},"OBSERVATIONAL","The goal of this observational study is to determine the durability of closure for venous leg ulcer subjects that achieved closure in the THOR trial.",[245,164,27,29,137],"Venous Leg","2025-01-22",{"date":248,"type":51},"2025-01-24",{"date":250,"type":19},"2025-01",{"date":252,"type":19},"2026-12",{"name":254,"class":58},"Kerecis Ltd.",{"id":256,"slug":257,"hasResults":11,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":4,"eligibilityCriteria":261,"healthyVolunteers":11,"sex":15,"minAge":262,"maxAge":263,"enrollmentInfo":264,"targetDuration":4,"studyType":20,"phases":266,"briefSummary":267,"conditions":268,"keywords":269,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":275,"leadSponsor":277,"locationsCount":4},"100574215","shock-wave-versus-low-level-laser-on-chronic-venous-ulcer-100574215","NCT06756386","Shock Wave Versus Low Level Laser on Chronic Venous Ulcer","Effect of Extra Corporeal Shock Wave Versus Low Level Laser on Chronic Venous Ulcer Healing","Inclusion Criteria:\n\n* All old age patients will be\n* Ranging from 45-60 years old\n* With BMI from (25-30)\n* Chronic venous ulcer grade 2 or 3\n* Ulcers non infected with superficial blood insufficiency\n* open ulcers.\n\nExclusion Criteria:\n\n* -Diabetes\n* hypertension\n* rheumatoid arthritis\n* Obesity\n* Musculoskeletal disorders\n* Dementia\n* cerbrovascular stroke\n* Deep venous thrombosis\n* deep venous ulcer\n* venous ulcer grade 4\n* smokers","45 Years","60 Years",{"count":265,"type":19},45,[22],"To find out the difference in the effect of shock wave therapy and low level laser therapy on venous ulcer patient As regards the following outcomes;\n\n1. medical state of patient no ( diabetes, hypertension,obesity,cancer , rheumatoid)\n2. The degree of ulcer\n3. recurrence of ulcer\n4. The degree of pain and disabilities\n5. inflammatory marker",[29],[270],"shock wave , low level laser","2025-01-01",{"date":273,"type":51},"2025-01-03",{"date":271,"type":19},{"date":276,"type":19},"2025-07-01",{"name":278,"class":212},"Beni-Suef University"]